Axsome Therapeutics (AXSM)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$0.95 (-0.95%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Axsome Therapeutics (AXSM)
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Key Insights

Critical company metrics and information
  • Share Price

    $99.54
  • Market Cap

    $4.82 Billion
  • Total Outstanding Shares

    48.46 Million Shares
  • Total Employees

    589
  • Dividend

    No dividend
  • IPO Date

    November 19, 2015
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.axsome.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow$-89.22 Million
Net Cash Flow From Investing Activities, Continuing$247000.00
Net Cash Flow From Financing Activities, Continuing$43.59 Million
Net Cash Flow From Investing Activities$247000.00
Net Cash Flow From Operating Activities$-132.57 Million
Net Cash Flow, Continuing$-89.22 Million
Net Cash Flow From Financing Activities$43.59 Million
Net Cash Flow From Operating Activities, Continuing$-132.57 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Operating Income/Loss$-306.22 Million
Other Operating Expenses$96.91 Million
Research and Development$162.87 Million
Costs And Expenses$644.68 Million
Preferred Stock Dividends And Other Adjustments$0.00
Diluted Earnings Per Share$6.58
Income/Loss From Continuing Operations After Tax$-310.95 Million
Net Income/Loss Available To Common Stockholders, Basic$-310.95 Million
Selling, General, and Administrative Expenses$384.90 Million
Income/Loss From Continuing Operations Before Tax$-311.28 Million
Operating Expenses$644.68 Million
Income Tax Expense/Benefit$325000.00
Basic Earnings Per Share$6.58
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Revenues$338.46 Million
Benefits Costs and Expenses$649.74 Million
Diluted Average Shares$143.75 Million
Basic Average Shares$143.75 Million
Net Income/Loss Attributable To Parent$-310.95 Million
Net Income/Loss$-310.95 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Noncurrent Liabilities$272.37 Million
Liabilities$468.56 Million
Other Non-current Assets$33.16 Million
Equity Attributable To Noncontrolling Interest$0.00
Equity Attributable To Parent$92.90 Million
Other Current Liabilities$112.57 Million
Liabilities And Equity$561.46 Million
Fixed Assets$683000.00
Accounts Payable$64.25 Million
Current Liabilities$196.19 Million
Wages$19.37 Million
Current Assets$479.11 Million
Equity$92.90 Million
Intangible Assets$48.50 Million
Noncurrent Assets$82.34 Million
Assets$561.46 Million
Inventory$14.27 Million
Other Current Assets$464.85 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.